BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $253,497,338 | -17.8% | 3,724,068 | -1.4% | 0.23% | -16.3% |
| Q2 2023 | $308,378,585 | +2.6% | 3,777,760 | -6.7% | 0.28% | -1.1% |
| Q1 2023 | $300,515,126 | -12.3% | 4,050,615 | -2.0% | 0.28% | -17.0% |
| Q4 2022 | $342,658,326 | +16.5% | 4,134,391 | +299.2% | 0.34% | +9.4% |
| Q3 2022 | $294,123,000 | -18.9% | 1,035,660 | -1.0% | 0.31% | -15.7% |
| Q2 2022 | $362,514,000 | -22.1% | 1,045,789 | -2.7% | 0.36% | -7.6% |
| Q1 2022 | $465,278,000 | -17.0% | 1,074,405 | -2.0% | 0.39% | -10.5% |
| Q4 2021 | $560,483,000 | +3.9% | 1,096,671 | -2.6% | 0.44% | -6.8% |
| Q3 2021 | $539,473,000 | +5.4% | 1,126,121 | -1.8% | 0.47% | +5.6% |
| Q2 2021 | $511,731,000 | +14.1% | 1,146,779 | -2.9% | 0.45% | +4.4% |
| Q1 2021 | $448,414,000 | +11.5% | 1,181,368 | -7.0% | 0.43% | +2.6% |
| Q4 2020 | $402,103,000 | +25.5% | 1,270,311 | -2.0% | 0.42% | +9.7% |
| Q3 2020 | $320,494,000 | -8.7% | 1,296,230 | -2.6% | 0.38% | -12.8% |
| Q2 2020 | $351,100,000 | +36.7% | 1,331,306 | -1.7% | 0.44% | +11.2% |
| Q1 2020 | $256,851,000 | -15.7% | 1,354,558 | -2.5% | 0.39% | +10.1% |
| Q4 2019 | $304,827,000 | +11.5% | 1,388,668 | -0.7% | 0.36% | +6.6% |
| Q3 2019 | $273,502,000 | -3.4% | 1,397,772 | +3.0% | 0.33% | -1.5% |
| Q2 2019 | $283,067,000 | +2.5% | 1,357,700 | -2.3% | 0.34% | +0.3% |
| Q1 2019 | $276,048,000 | +33.8% | 1,390,320 | -2.5% | 0.34% | +17.4% |
| Q4 2018 | $206,278,000 | -33.9% | 1,425,361 | -6.8% | 0.29% | -18.6% |
| Q3 2018 | $312,006,000 | +33.1% | 1,528,618 | -3.5% | 0.35% | +36.7% |
| Q2 2018 | $234,390,000 | -5.7% | 1,584,254 | -3.7% | 0.26% | -8.8% |
| Q1 2018 | $248,537,000 | +14.0% | 1,645,507 | -2.3% | 0.28% | +13.1% |
| Q4 2017 | $218,092,000 | +1.2% | 1,683,455 | -5.6% | 0.25% | -7.0% |
| Q3 2017 | $215,546,000 | -0.1% | 1,782,991 | -2.9% | 0.27% | -2.5% |
| Q2 2017 | $215,716,000 | +11.7% | 1,835,883 | -3.4% | 0.28% | +11.2% |
| Q1 2017 | $193,185,000 | +17.1% | 1,900,495 | +18.4% | 0.25% | +12.2% |
| Q4 2016 | $165,011,000 | -0.0% | 1,604,693 | +6.4% | 0.22% | -0.9% |
| Q3 2016 | $165,093,000 | -4.9% | 1,507,696 | -2.0% | 0.22% | -6.3% |
| Q2 2016 | $173,544,000 | +25.1% | 1,538,916 | +4.9% | 0.24% | +25.1% |
| Q1 2016 | $138,674,000 | +2.2% | 1,467,144 | -2.7% | 0.19% | +7.3% |
| Q4 2015 | $135,732,000 | +14.0% | 1,508,132 | +17.1% | 0.18% | +16.3% |
| Q3 2015 | $119,099,000 | +13.7% | 1,288,117 | +21.1% | 0.15% | +31.9% |
| Q2 2015 | $104,761,000 | +1.5% | 1,063,885 | +3.3% | 0.12% | +5.5% |
| Q1 2015 | $103,261,000 | +60.5% | 1,029,623 | +47.9% | 0.11% | +64.2% |
| Q4 2014 | $64,341,000 | – | 696,339 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |